Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned an average recommendation of "Buy" from the ten analysts that are covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.31.
Several brokerages have recently weighed in on TRVI. D. Boral Capital restated a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright raised their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a "buy" rating in a research note on Thursday, December 12th.
View Our Latest Stock Report on TRVI
Trevi Therapeutics Price Performance
NASDAQ TRVI traded down $0.20 during trading hours on Friday, hitting $4.60. The company had a trading volume of 1,897,086 shares, compared to its average volume of 663,057. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $5.05. The company has a market capitalization of $353.58 million, a price-to-earnings ratio of -10.45 and a beta of 0.88. The firm's 50 day moving average is $4.08 and its 200 day moving average is $3.37.
Institutional Investors Weigh In On Trevi Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. raised its holdings in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after acquiring an additional 2,894 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after purchasing an additional 6,764 shares during the period. Raymond James Financial Inc. bought a new stake in Trevi Therapeutics in the fourth quarter valued at about $49,000. Squarepoint Ops LLC bought a new stake in Trevi Therapeutics in the fourth quarter valued at about $58,000. Finally, Two Sigma Advisers LP bought a new stake in Trevi Therapeutics in the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free ReportTrevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Recommended Stories
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
